Poly-β-1,6-N-acetylglucosamine (PNAG) (PNAG)

Poly-β-1,6-N-acetylglucosamine (PNAG) is a highly conserved surface exopolysaccharide produced by numerous Gram-positive and Gram-negative bacterial pathogens, including Staphylococcus aureus, Escherichia coli, and Klebsiella pneumoniae (Cywes-Bentley et al., 2013). It plays a fundamental role in the formation and structural integrity of biofilms, where it acts as a "molecular glue" for intercellular adhesion (Götz, 2002). Beyond its structural role, PNAG shields bacteria from the host immune system by inhibiting opsonophagocytosis and complement-mediated killing (Kropec et al., 2005). As a therapeutic target, PNAG is particularly attractive due to its prevalence across diverse species, making it a candidate for broad-spectrum vaccines and monoclonal antibody therapies (Skurnik et al., 2010). Current drug development efforts focus on humanized monoclonal antibodies like F598 and synthetic conjugate vaccines designed to elicit protective immune responses against PNAG-producing organisms (Pier, 2012). Additionally, the enzyme Dispersin B is studied for its ability to specifically degrade PNAG, thereby dispersing biofilms and increasing bacterial susceptibility to conventional antibiotics (Kaplan et al., 2004).

Other names

PNAGPolysaccharide Intercellular AdhesinPIAPoly-N-acetylglucosaminedPNAG

Monoclonal antibodies bind to PNAG to facilitate opsonophagocytic killing by host immune cells, while vaccines induce protective antibody responses; enzymatic agents like Dispersin B hydrolyze the glycosidic bonds to disrupt biofilm architecture.